ERIC DOBMEIER
CIK 1202785 · President, CEO · last filed 2026-06-18
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$442.1K
Companies
9
Total Filings
129
Lifetime Open-Market Net
-$38.16M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| GPCR | Director | — | $47.89 | — | $0 | 3 | 2026-06-18 |
| JANX | Director | 15,481 | $15.00 | $232.2K | $0 | 4 | 2026-06-12 |
| JBIO | Director | — | $19.70 | — | $0 | 2 | 2026-06-11 |
| ATRA | Director | 22,533 | $7.81 | $176.0K | $236.9K | 13 | 2023-11-14 |
| CHINOOK THERAPEUTICS, INC. (KDNY) Delisted | President, CEO | 0 | $40.39 | $0 | -$1.79M | 22 | 2023-08-11 |
| ADPT | Director | 1,504 | $22.52 | $33.9K | -$2.70M | 12 | 2021-02-17 |
| Aravive, Inc. (VSAR) Delisted | Director | 3,027 | — | — | $0 | 2 | 2017-12-22 |
| Seagen Inc. (SGEN) Delisted | Chief Operating Officer | 117,424 | $228.74 | $26.86M | -$33.92M | 66 | 2017-12-06 |
| STEMLINE THERAPEUTICS INC (STML) Delisted | Director | 27,963 | — | — | $0 | 4 | 2017-06-20 |
Recent Filings · Page 2 of 13
129 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2023-08-11 | CHINOOK THERAPEUTICS, INC. (KDNY) Delisted | Disp (D) | −301,138 | $0 | EDGAR |
| 2023-06-02 | ATRA | Grant (A) | +57,000 | $0 | EDGAR |
| 2023-04-26 | CHINOOK THERAPEUTICS, INC. (KDNY) Delisted | Mixed | +2,400 | -$476.3K | EDGAR |
| 2023-04-24 | — | Notice (144) | −25,000 | -$540.2K | EDGAR |
| 2023-02-15 | CHINOOK THERAPEUTICS, INC. (KDNY) Delisted | Mixed | +12,151 | -$192.3K | EDGAR |
| 2023-02-01 | CHINOOK THERAPEUTICS, INC. (KDNY) Delisted | Mixed | +17,311 | -$792.9K | EDGAR |
| 2022-12-15 | CHINOOK THERAPEUTICS, INC. (KDNY) Delisted | Exer (M) | +30,000 | $10.5K | EDGAR |
| 2022-12-02 | CHINOOK THERAPEUTICS, INC. (KDNY) Delisted | Mixed | +5,000 | -$644.2K | EDGAR |
| 2022-10-11 | CHINOOK THERAPEUTICS, INC. (KDNY) Delisted | Exer (M) | +30,796 | $0 | EDGAR |
| 2022-06-27 | ATRA | Grant (A) | +20,500 | $0 | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.